ALIM

Alimera Sciences, Inc. (ALIM) | Rumor.io

Alimera Sciences

ALIM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ALIM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% new	0% +0

May 22

Alimera Sciences, Inc. (ALIM) is mentioned in a post discussing its potential impact on the gold market.
The post does not provide specific information about ALIM's performance or future prospects.
The author mentions a link to OKX, a cryptocurrency exchange, but does not provide any further details about ALIM.

Generated by AI

Sentiment

Of the messages about ALIM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +41.67
Bearish	—	—	—	0% -41.67

Bullish· Jun 24

Alimera Sciences ($ALIM) saw an 80% price increase following premarket news.
The company is expected to experience substantial accretion in adjusted non-GAAP EPS in 2025 and beyond, thanks to a deal with ANI Pharmaceuticals.
The takeover deal by ANI Pharmaceuticals is anticipated to deliver significant additional revenue, including $35M-$38M in 2025 adjusted non-GAAP EBITDA.

Bearish· May 18

The company's market capitalization is under $20 million, which may not be sufficient to protect its consolidated net revenue of at least $100 million.
The stock's price action is described as "inexplicable" and "manipulative," suggesting that the market may be subject to external influences.
The stock's erratic price movement may be caused by short sellers, with some users suggesting that the company is being targeted by a short attack.

Generated by AI

Topics

Of the messages about ALIM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	0%	0%	0%	0.07%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	100%	100%	100%	99.93%
Technical Analysis	0%	0%	0%	0%

Earnings· Jul 30

$ALIM beats on revenue in earnings report.
Alimera Sciences, Inc. reports a loss of $0.06 in earnings, in line with consensus.
Alimera Sciences, Inc. will release earnings on 7/30 after close.

Announcements· Sep 11

Alimera Sciences, Inc. ($ALIM) and ANI Pharmaceuticals, Inc. ($ANIP) have jointly announced the closing date of their merger for September 16, 2024.
The merger was previously announced, and the companies have scheduled the closing of the transaction before the market opens on September 16, 2024.
The closing of the merger has been delayed, which has led to a Truist downgrade of ANI Pharmaceuticals ($ANIP) to Hold from Buy, citing potential manufacturing issues with Yutiq.

Generated by AI

Community

Of the messages about ALIM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	0%
Newcomers	100%	100%	100%	100%

Regulars· Jun 24

Alimera Sciences ($ALIM) has agreed to be acquired by ANI Pharmaceuticals ($ANIP) in a deal valued at around $381M, with ANI offering $5.50 per share in cash and a non-tradable contingent value right (CVR) of up to $0.50 per share.
The acquisition price represents a 75% premium to Alimera's closing share price of $3.15 on June 21, 2024, and ANI will also repay $72.5M of Alimera's debt.
Alimera Sciences' stock price surged 76% amid heavy trading after the acquisition announcement, with the stock closing at $5.54 and gaining 2.39% to reach a 75.87% increase.

Newcomers· Jun 24

The buyout price of Alimera Sciences, Inc. (ALIM) is $5.50 per share in cash, with a contingent value right (CVR) representing the right to receive up to $0.50.
The acquisition is expected to close with ANI Pharmaceuticals Inc. (ANIP) paying approximately $381 million in upfront consideration.
The transaction will see Alimera Sciences, Inc. (ALIM) shareholders receive a roughly 75% premium to the company's Friday close.

Generated by AI

Also Discussed

Investors talking about ALIM also mention

#	Name	Attention
1	EyePoint, Inc. Common StockEYPT	0%0
2	EVOK - Evoke Pharma, Inc.	——
3	MRNS - Marinus Pharmaceuticals, Inc.	——
4	BLPH - Bellerophon Therapeutics, Inc.	——
5	MACK - Merrimack Pharmaceuticals, Inc.	——
6	BCEI - Civitas Resources, Inc.	——
7	Catalyst Pharmaceuticals Inc.CPRX	0%new
8	Hudson Technologies, Inc.HDSN	0.01%new
9	SINO - Singularity Future Technology Ltd.	——
10	Corgi All Commodities 2x Daily ETFXCOM	0%0